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Introduction
The COVID-19 pandemic caused by Severe Acute 
Respiratory Virus 2 (SARS-CoV-2) is a serious public 
health crisis in the history of humanity. Originated in 
Wuhan, China, SARS-CoV-2 has spread to every corner 
of the world within a few months. As of March 22, 
2021, over 123 million confirmed cases and 2.72 million 
deaths have been reported from over 219 countries [1].
As the virus is moving fast, various clinical spectrum 
and differential clinical outcomes are unfolding across 
different geographic locations. Several symptoms have 
been reported which includes fever, cough, myalgia, 
sputum production, headache, hemoptysis, diarrhea, and 
dyspnea [2]. The severity of COVID-19 has been reported 
to be linked with various host factors including diabetes, 
hypertension, cardiovascular disease, chronic obstructive 
pulmonary disease (COPD), malignancy, and chronic liver 
disease [2]. While susceptibility to COVID-19 covers all 
age groups, people with compromised immune systems 
and or having comorbidity are at a higher risk [3, 4]. A few 
review studies investigated symptoms and comorbidities 
of the COVID-19 infected patients with a shorter 
time-frame  [3,  5-8]. The mortality rate is high in older 
COVID-19 patients with organ dysfunctions comprising 
shock, acute respiratory distress syndrome (ARDS), acute 
cardiac injury, and acute kidney injury [9]. However, there 
is a scarce information regarding the relationship between 
symptoms, comorbidities, and age of the COVID-19 
patients. The objective of this study was to estimate the 
prevalence of all reported symptoms and comorbidities, 
and then identified the risk factors associated with age of 
COVID-19 infected patients.
Methods
The PRISMA-P-2009 guidelines was followed in our 
systematic review and meta-analysis (PROSPERO 
registration: CRD42020182677) [10].
Data sources and search strategy 
The major databases, such as PubMed, SCOPUS, 
EMBASE, WHO, Semantic Scholar, and COVID-19 
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Primer were searched to include peer-reviewed and pre-
proof research articles. The mortality starts falling at the 
end of April 2020 [11] and we limited our review within 
initial period to high mortality period. Also, our literature 
search strategy covered almost hundred percent of the 
COVID-19 symptoms and comorbidities, and the overall 
sample size for our data analysis was sufficiently large 
[n = 4,884]. Therefore, we restricted our search language 
in only English literature within the time period January 
to April, 2020.
The search terms used included: “COVID-19” OR 
“COVID-2019” OR “severe acute respiratory syndrome 
coronavirus 2” OR “2019-nCoV” OR “2019nCoV” OR 
“nCoV” OR “SARS-CoV-2” OR “coronavirus” AND 
“clinical for epidemiological characterization” OR 
“Symptom” OR “Symptoms” AND “comorbidity” OR 
“comorbidities”. Some articles were manually retrieved 
from Google Scholar and other databases. We also 
searched the reference lists of the selected publications. 
MMR, BB, and MJU independently screened the titles 
and abstracts of the articles and checked full-text 
eligibility (Tab. I).
Inclusion/exclusion criteria
Research articles were selected if they reported clinical 
characteristics (both symptoms and comorbidities) 
of the COVID-19 patients. The inclusion criteria for 
studies were: clinical investigations or consecutive 
cases; focused on infected patients; reported at least ten 
cases and considered all age-groups from any countries. 
Studies were excluded if they were: grey literature, case 
report, and secondary studies; specific to children or 
pregnant women; less than 10 small sample; and only 
reported symptoms or comorbidities. A standardized 
form was used to extract data from eligible studies. 
Disagreements were resolved through discussion 
with co-reviewers. For each study, publication details, 
research design and the participants’ characteristics with 
major findings were recorded.
Data quality assessment and analysis
The quality of each study was assessed by ZF using 
Joanna Briggs Institute (JBI) guidelines  [12]. A set of 
eight questions was used for the quality assessment. 
Random effect model was used to estimate the 
prevalence of all reported symptoms and comorbidities 
in the COVID-19 patients. Heterogeneity was assessed 
using the Cochran Q and the I2 statistic  [13,  14]. We 
performed Egger test (p < 0.001) to examine the presence 
of publication bias and small-study effects. Multivariate 
analysis [multivariable factor analysis (MFA)] was 
performed to examine the correlation/association 
among symptoms and comorbidities with the patients’ 
age [15, 16]. All statistical analyses were conducted by 
Stata version 15 (Stata Corp, College Station, TX) using 
the metaprop, metabias; and R-programming language 
using the FactoMineR package.
Supplementary Table S1 have provided in the 
supplementary file. Please see supplementary file.
Results
A total of 799 articles (databases: 791, other sources: 8) 
were retrieved. Of them, 403 articles were removed due 
to duplication and irrelevance. Furthermore, 303 review 
articles, editorials, case reports, and irrelevant study 
populations were excluded. Fifty-three articles were 
excluded as they failed to meet all inclusion criteria. 
Finally, eleven articles were excluded due to not peer-
reviewed and small sample sizes, resulting in the 
selection of 29 articles for our review. The PRISMA 
flow diagram visualizes the screening process of selected 
studies (Fig. 1).
Supplementary Table S1 summarizes the characteristics 
of the selected studies and 83% of selected studies for this 
meta-analysis were reported from China. Five studies 
were conducted in the USA, India, Spain, and South 
Korea. The overall sample size was 4,884 COVID-19 
patients, with an age range of 10 to 92 years. Among 
the patients, 2,675 (55%) were male, and 2,208 (45%)
were female. The sample size ranged from 12 to 1,099 
patients, where most studies (79%) had a retrospective 
research design.
Altogether, 33 symptoms and 43 comorbidities were 
found. Almost all the studies reported fever (proportion of 
Tab. I. Search strategy used in different databases.
PubMed SCOPUS/EMBASE WHO/Semantic Scholar
ALL ( “COVID-19” OR “COVID-2019” OR 
“severe acute respiratory syndrome 
coronavirus 2” OR “severe acute 
respiratory syndrome coronavirus 2” 
OR “2019-nCoV” OR “nCoV” OR “SARS-
CoV-2” OR “2019nCoV” OR “coronavirus” 
) AND ALL ( “clinical for epidemiological 
characterization” OR “Symptom” OR 
“Symptoms” ) AND ALL ( “comorbidity” OR 
“comorbidities” AND full text[sb] AND ( 
“2019/12/31”[PDat] : “2020/04/30”[PDat] ) 
AND Humans[Mesh]
ALL ( “COVID-19” OR “COVID-2019” OR 
“severe acute respiratory syndrome 
coronavirus 2” OR “severe acute 
respiratory syndrome coronavirus 2” 
OR “2019-nCoV” OR “nCoV” OR “SARS-
CoV-2” OR “2019nCoV” OR “coronavirus” 
) AND ALL ( “clinical for epidemiological 
characterization” OR “Symptom” OR 
“Symptoms” ) AND ALL ( “comorbidity” 
OR “comorbidities” ) AND ( LIMIT-TO ( 
LANGUAGE , “English” ) ) AND ( LIMIT-TO 
( PUBYEAR , 2020 ) ) AND ( LIMIT-TO ( 
DOCTYPE , “ar” ) OR LIMIT-TO ( DOCTYPE , 
“re” ) )
(“COVID-19” OR “COVID-2019” OR “severe 
acute respiratory syndrome coronavirus 
2” OR “severe acute respiratory syndrome 
coronavirus 2” OR “2019-nCoV” OR 
“nCoV” OR “SARS-CoV-2” OR “2019nCoV” 
OR “coronavirus”) AND (“clinical or 
epidemiological characterization” OR 
“Symptom” OR “Symptoms”) AND 
(“comorbidity” OR “comorbidities”)
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patients ranging from 25 to 100%), cough/dry cough (22-
92%) and myalgia or muscle ache (3-63%) as common 
symptoms of COVID-19. Other reported symptoms were: 
headache (3-66%); diarrhea (3-48%); fatigue/weakness 
(9-85%); dyspnea/shortness of breath (1-88%); sputum 
production or expectoration (4-42%); vomiting (1-19%); 
nausea (4-27%); chest tightness (7-55%); and sore throat 
(5-32%). For the comorbidities, about 93% and 86% of 
studies reported two comorbidities: diabetes (2 to 35%) 
and hypertension (8-50%). Other prevalent comorbidities 
were chronic obstructive pulmonary disease (COPD)/
lung infection (0.2-38%); cardiovascular disease (5-
23%); chronic liver disease (1-29%); malignancy (1-7%); 
coronary heart disease (1-33%); cerebrovascular disease 
(1-19%); chronic renal disease (1-8%); chronic kidney 
disease (1-29%); and Acute respiratory distress syndrome 
(ARDS) (17-100%). The less reported symptoms and 
comorbidities were presented in Supplementary Table S1.
Meta-analysis of symptoms and comorbidities
We meta-analysed 19 symptoms and 11 comorbidities, 
using random effect models that were reported in at 
least five selected articles (Tab.  II and Supplementary 
Figs S2-S31). Meta-analysis showed a higher prevalence 
of fever (pooled prevalence: 84, 95% confidence interval 
(CI): 80-88%) and cough/dry cough (61, 95% CI:  55-
67%); followed by fatigue/weakness (42, 95% CI: 34-
51%); dyspnea/shortness of breath (39, 95% CI:  27-
51%); headache and diarrhea (12, 95% CI: 8-17%); sore 
throat (15, 95% CI: 11-20%); myalgia/muscle ache and 
sputum production/expectoration (24, 95% CI: 18-30%); 
rhinorrhea (13, 95% CI: 4-26%); chest tightness (25, 95% 
Fig. 1. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow diagram for the study selection process.
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CI: 15-31%); and anorexia (26, 95% CI: 16-38%). The 
less prevalent symptoms were: chest pain (3%), nausea 
(8%), vomiting (6%), abdominal pain (4%), dizziness 
(5%), pharyngalgia (7%), and hemoptysis (2%).
The most prevalent comorbidities were ARDS (61, 
95% CI: 15-97%), hypertension (23, 95% CI: 18-
28%), and diabetes (12, 95% CI: 9-15%), followed by 
cardiovascular disease (10, 95% CI: 7-13%); coronary 
heart disease (7, 95% CI:  3-12%); cerebrovascular 
disease (6, 95% CI:  2-08%); COPD/lung disease (3, 
95% CI: 02-50%); chronic liver disease (05, 95% CI: 03-
07%); chronic Renal disease (0.01, 95% CI: 00%-03%); 
chronic Kidney disease (05, 95% CI: 02-10%); and 
malignancy (03, 95% CI: 02-04%).
There was a high heterogeneity (I2 ranged from 85 to 
97%, Cochran Q-statistic p < 0.001) in all the prevalence 
of symptoms, except chest pain (I2  =  0%, Cochran 
Q-statistic p  <  0.95); abdominal pain (I2  =  22.89%, 
Cochran Q-statistic p < 0.26); dizziness (I2 = 64.21%, 
Cochran Q-statistic p  <  0.002); and haemoptysis 
(I2 = 63.48%, Cochran Q-statistic p < 0.01). In the case 
of comorbidities, the heterogeneity was found higher 
in almost all the comorbidities (I2 ranged from 68.06 to 
98.01%, Cochran Q-statistic p < 0.001) (Tab. II).
Symptoms and comorbidity factors associated 
with age of COVID-19 infected Patients
Nineteen symptoms and 11 comorbidities were 
categorized into: symptom group and comorbidity 
group to determine the association between symptoms/
comorbidities and age of the COVID-19 patients 
(Fig.  2). In factor analysis, the correlation circle 
represented between/within-group integration with 
the patients’ age. The longer vectors indicated more 
influential than others, and the vectors that were close 
to each other with the same direction indicated a highly 
positive association. Vectors that were the opposite 
direction showed a negative association, and the 
vectors with an almost 90-degree angle demonstrated 
no association. The first principal component showed 
31.59% variation and the second one showed 20.45% 
variation in the dataset.
Tab. II. Overall prevalence summary for clinical symptoms and comorbidities of the COVID-19 patients.
Clinical characteristics
(symptoms)






Fever 29 (100%) 4,115 0.84 (0.80-0.88) 90.670 < 0.001 < 0.001
Cough/dry cough 29 (100%) 3,039 0.61 (0.55-0.67) 93.400 < 0.001 0.382
Fatigue/Weakness 21 (72.41%) 1,627 0.42 (0.34-0.51) 96.320 < 0.001 0.107
Dyspnoea/shortness of breath 18 (62.06%) 920 0.39 (0.27-0.51) 97.370 < 0.001 < 0.001
Headache 22 (72.86%) 448 0.12 (0.09-0.16) 89.980 < 0.001 0.109
Diarrhoea 22 (72.86%) 474 0.12 (0.08-0.17) 93.720 < 0.001 0.004
Sore throat 9 (31.03%) 348 0.15 (0.11-0.20) 84.990 < 0.001 0.266
Myalgia/muscle ache 25 (86.20%) 925 0.24 (0.18-0.30) 95.000 < 0.001 < 0.001
Rhinorrhoea 5 (17.24%) 48 0.13 (0.04-0.26) 88.010 < 0.001 0.088
Sputum production/expectoration 15 (51.72%) 1,066 0.24 (0.19-0.30) 92.310 < 0.001 0.956
Chest tightness 11 (37.93%) 462 0.25 (0.15-0.31) 88.440 < 0.001 0.527
Chest pain 5 (17.24%) 15 0.03 (0.01-0.04) 0.000 < 0.95 0.878
Nausea 12 (41.37%) 238 0.08 (0.04-0.12) 91.780 < 0.001 0.023
Vomiting 14 (48.27%) 209 0.06 (0.03-0.09) 88.330 < 0.001 0.096
Abdominal pain 6 (20.68%) 42 0.04 (0.03-0.06) 22.890 < 0.26 0.431
Dizziness 6 (20.68%) 71 0.05 (0.03-0.08) 64.21 < 0.002 0.132
Anorexia 7 (24.13%) 339 0.26 (0.16-0.38) 94.470 < 0.001 < 0.001
Pharyngalgia 6 (20.68%) 86 0.07 (0.04-0.13) 88.030 < 0.001 0.017
Haemoptysis 7 (24.13%) 47 0.02 (0.01-0.04) 63.480 < 0.01 0.005
Comorbidity
Diabetes 27 (93.10) 539 0.12 (0.09-0.15) 83.09 < 0.001 0.009
Hypertension 25 (86.20) 1,096 0.23 (0.18-0.28) 93.24 < 0.001 0.149
Cardiovascular disease 15 (51.72) 212 0.1 (0.07-0.13) 73.96 < 0.001 0.031
Coronary heart disease 10 (34.48) 141 0.07 (0.03-0.12) 92.21 < 0.001 0.007
Cerebrovascular disease 10 (34.48) 100 0.06 (0.02-0.08) 90.77 < 0.001 0.004
COPD/lung disease 21 (72.41) 136 0.03 (0.02-0.05) 86.67 < 0.001 < 0.001
Chronic liver disease 15 (51.72) 96 0.05 (0.03-0.07) 78.23 < 0.001 < 0.001
Chronic renal disease 9 (31.03) 32 0.01 (0.00-0.03) 54.63 < 0.001 0.003
Chronic kidney disease 6 (20.68) 41 0.05 (0.02-0.10) 86.69 < 0.001 0.036
Malignancy 15 (51.72) 82 0.03 (0.02-0.04) 68.06 < 0.001 < 0.001
ARDS** 4 (13.79) 111 0.61 (0.15-0.97) 98.01 < 0.001 0.301
** ARDS reported in four studies and we include this study into our analysis because it showed higher prevalence rate.
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In symptom group, fever, dyspnea/shortness of breath, 
nausea, vomiting, abdominal pain, dizziness, anorexia, 
and pharyngalgia were found positively associated 
with the COVID-19 patients’ age. In contrast, sore 
throat, headache, rhinorrhea, myalgia/muscle ache, 
fatigue, and hemoptysis were negatively associated 
with age. Similarly, in the comorbidity group, diabetes, 
hypertension, coronary heart disease, COPD/lung 
disease, and ARDS were in the same direction and 
positively associated with the age of the COVID-19 
infected patients. The symptoms like chest tightness/
pain and the comorbidities, including chronic liver 
and kidney diseases, showed no association with the 
patients’ age.
Considering group integration, the fever, dyspnea/
shortness of breath, dizziness, pharyngalgia, and anorexia 
in the symptom group were positively associated with 
diabetes, ARDS, and kidney, cardiovascular, and liver 
diseases in comorbidity group. The symptoms like 
diarrhea, nausea, vomiting, and abdominal pain were 
positively associated with hypertension, coronary heart 
disease, and COPD/lung disease. The symptoms of sore 
throat, headache, rhinorrhea, myalgia/muscle ache, 
fatigue, and hemoptysis were positively associated with 
cerebrovascular disease (Fig. 2).
Table  III summarizes the quality assessment of the 
selected studies. In 16 (55%) studies, participant 
recruitment method was appropriate, while the method 
was unclear in 45% studies. Thirteen (45%) studies 
had a sample size of more than 100, and about 96% 
of studies reported the subjects and design in detail. 
Validated methods were used in all studies, where the 
measurement was reliable, and the response rate was 
100% (Tab. III).
The Egger test of symptoms – fever, dyspnea/shortness of 
breath, diarrhea, myalgia/muscle ache, nausea, anorexia, 
pharyngalgia, and hemoptysis – were found significant 
(p < 0.05), which suggested the presence of small-study 
effects. The comorbidities- diabetes, cardiovascular 
disease, cerebrovascular disease, COPD/lung disease, 
chronic liver disease, chronic renal disease, chronic 
kidney disease, and malignancy were found significant 
(p  <  0.05) by the Egger’s test, that recommended the 
presence of small-study effects. 
Discussion
We aimed to estimate the prevalence of all reported 
symptoms and comorbidities, and investigate the 
factors associated with age of patients tested positive 
in COVID-19. In our selected 29 studies, the ratio 
Fig. 2. Group association of symptoms and comorbidities with age of the COVID-19 patients (Symptom Group: S1: Fever, S2: Cough/Dry 
cough, S3: Fatigue, S4: Dyspnea/Shortness of breath, S5: Headache, S6: Diarrhea, S7: Sore Throat, S8: Myalgia/Muscle Ache, S9: Rhinorrhea, 
S10: Sputum Production/Expectoration, S11: Chest tightness, S12: Chest pain, S13: Nausea, S14: Vomiting, S15: Abdominal Pain, S16: Diz-
ziness, S17: Anorexia, S18: Pharyngalgia, S19: Haemoptysis. Comorbidity Group: C1: Diabetes, C2: Hypertension, C3: Cardiovascular Disease, 
C4: Coronary heart disease, C5: Cerebrovascular disease, C6: COPD/Lung disease, C7: Chronic liver disease, C8: Chronic Renal disease, C9: 
Chronic Kidney disease, C10: Malignancy, C11: ARDS).
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of infection was reported higher in males than in 
females (100:82.5), and this result is consistent with 
previous studies [2, 5, 27, 45]. It is generally assumed 
that males are more likely to be infected by bacteria 
and viruses than females, because of the women’s 
robust innate and adaptive immune responses [3, 46]. 
Moreover, males are more vulnerable to infectious 
disease because of different patterns of occupation, 
social communication, and lifestyle than females. 
Furthermore, in many developing countries, women 
are housewives who stay at home and have little 
contact with others [47].
We found 33 symptoms and 43 comorbidities in 
the studies, and our meta-analysis included most 
reported 19 symptoms and 11 comorbidities. Fever, 
cough/dry cough, fatigue, dyspnea, anorexia, chest 
tightness, myalgia, sore throat, rhinorrhea, headache, 
and diarrhea were highly prevalent symptoms 
where the others symptoms were found rarely. All 
studies reported fever (84%) and cough/dry cough 
(61%) as symptoms consistent with relevant studies 
across the countries  [19,  23,  25,  48]. Previous 
studies reported hypertension as the most common 
comorbidity [3, 6, 7], but our study suggests three major 
comorbidities  –  acute respiratory distress syndrome 
(61%), hypertension (23%), and diabetes (12%). Acute 
respiratory distress syndrome was found a higher 
prevalence rate (61%) as reported in three studies in 
China and one in outside China  [28, 32, 36, 44]. We 
observed that the symptoms like anorexia (26%), 
chest tightness (25%) and rhinorrhea (13%), and one 
comorbidity, i.e., acute respiratory distress syndrome 
(61%) were examined with significant prevalence, but 
they were under-reported in the published systematic 
reviews [5, 6, 49, 50].
Human aging is associated with declines in adaptive 
and innate immunity, and it loses the body’s ability 
to protect against infections  [51-53]. Virologists and 
clinicians agree that the older adults are more vulnerable 
to COVID-19, and the patient’s age can strongly be 
associated with symptoms and comorbidities [30, 54-
57]. Our multivariate analysis revealed that a cluster 
of symptoms, including fever, dyspnea/shortness of 
breath, nausea, vomiting, abdominal pain, dizziness, 
anorexia, and pharyngalgia, as well as a cluster of 
comorbidities, including diabetes, hypertension, 
coronary heart disease, COPD/lung disease, and 
ARDS, were positively associated with the age of 
COVID-19 infected patients. The Centers for Disease 
Control and Prevention (CDC) suggested that the 
older adults are more likely to be asymptomatic and 
they are at greater risk of requiring hospitalization 
or dying if they are diagnosed with COVID-19  [58]. 
The comorbid conditions (e.g. hypertension, heart 
problems, diabetes) and disease symptoms were 
more severe in the elderly age than any other age 
groups  [59-63]. In a study, Wu Z and the authors 
reported that the COVID-19 infected elderly aged 
above 80 years had a higher case fatality rate (14.8 
vs 8.0%) than 70-80 years aged peoples  [64]. The 
World Health Organization (WHO) reported that older 
people with pre-existing medical conditions including 
asthma, diabetes, and heart disease appear to be more 
vulnerable to becoming severely ill with the virus and 
this findings supports to many other studies [65-68]. 
During literature search, we were limited to only in 
English texts within the time frame January to April, 
2020. The majority of the studies were found in China, 
and only five from other countries. More studies outside 
of China could add value in prevalence estimation. We 
found no data for <10 years children and thus, more 
studies are warranted in the child COVID-19 patients. 
Lastly, a few studies were found low sample size.
Conclusions
This review study is the unique effort of its kind that 
estimated all frequent symptoms and comorbidities, 
and determines the age related risk factors of the 
COVID-19 patients. We found a cluster of symptoms and 
comorbidities that were the age associated risk factors 
of patients infected in COVID-19. Thus, in very early 
stages of SARS-CoV-2 infection, if a patient exhibits any 
of the symptoms within the cluster, this patient should 
be isolated and the necessary actions should be taken. 
Our findings also suggest a prioritize vaccination by age 
groups and older people with underlying conditions. 
Finally, policymakers should develop a comprehensive 
mass media campaign to educate the general population 
about these symptoms and comorbidities.
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 Liu et al. 07.02.2020 Hubei, China Retrospective 57 137 61 76 Both 0.82 0.48 0.32 0.19 0.10 0.08 
 Jin et al. 24.03.2020 Zhejiang, China Retrospective 46 651 331 320 Both 0.84 0.67 0.18 N/M 0.10 N/M 
Wang et al. 17.03.2020 Wuhan, China Retrospective, 
single center 
56 138 75 63 Both 0.99 0.59 0.70 0.31 0.07 0.10 
Yuan et al. 19.03.2020 Hubei, China Retrospective 60 27 12 15 Both 0.78 0.59 N/M 0.41 N/M N/M 
Guan et al. 28.02.2020 China (30 
provinces) 
Cohort 47 1099 639 460 Both 0.89 0.68 0.38 N/M 0.14 0.04 
Liu et al. 27.03.2020 Hainan, China Retrospective 68 56 31 25 Both 0.76 0.36 0.09 N/M N/M N/M 
Zhou et al. 12.03.2020 Wuhan, China N/M 51 254 115 139 Both 0.84 0.39 0.52 0.04 0.11 N/M 
Huang et al. 24.01.2019 Wuhan, China Cohort 49 41 30 11 Both 0.98 0.76 0.44 0.55 0.08 0.03 
 Chen et al. 29.01.2019 Wuhan, China Retrospective, 
single center 
55.5 99 67 32 Both 0.83 0.82 N/M N/M 0.08 0.02 
 Du et al. 3.04.2020 Wuhan, China Retrospective 66 85 62 23 Both 0.92 0.22 0.59 0.71 0.05 0.19 
 Xu et al. 28.02.2020 Guangzhou, China N/M 50 90 39 51 Both 0.78 0.63 0.21 N/M 0.04 0.06 
Goyal et al. 17.04.2020 New York, USA Retrospective 62 393 238 155 Both 0.77 0.79 N/M 0.57 N/M 0.24 
Barrasa et al. 1.04.2020  Vitoria, Spain N/M 63 48 27 21 Both 1.00 0.73 N/M 0.88 N/M N/M 
 Yan et al. 12.4.2020 USA Cross sectional 48.5 59 29 29 Both 0.70 0.66 0.81 0.54 0.66 0.48 
 Gupta et al. 6.04.2020 New Delhi, India Retrospective, 
Observational 
40 21 14 7 Both 0.43 0.43 N/M N/M 0.14 N/M 
Yang et al. 21.02.2020 Wenzhou, China Retrospective 
cohort 
45 149 81 68 Both 0.77 0.58 N/M 0.01 0.09 0.07 
 Han et al. 15.04.2020 Wuhan, China Retrospective 62.5 206 91 115 Both 0.67 0.26 0.45 N/M N/M 0.33 
 Kim et al. 6.04.2020 South Korea Cohort 40 28 15 13 Both 0.25 0.29 0.11 N/M 0.25 0.11 
 Wang et al. 15.03.2020 Wuhan, China Retrospective, 
single-centre 
69 339 166 173 Both 0.92 0.53 0.40 0.41 0.04 0.13 
 Shi et al. 24.02.2020 Wuhan, China Retrospective 49.5 81 42 39 Both 0.73 0.59 0.09 0.42 0.06 0.04 
Yang et al. 21.02.2020 Wuhan, China Retrospective, 
single-centre, 
Observational 
60 52 35 17 Both 0.98 0.77 N/M 0.64 0.06 N/M 
N/M: Not Mentioned 
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Others No. of 
Sympt
oms 




 Zhang et al.  N/M N/M N/M N/M 0.31 N/M 0.17 N/M 0.06 N/M 0.17 N/M N/M N/M 9 
 Xu et al. N/M 0.52 N/M N/M N/M N/M N/M N/M N/M N/M N/M N/M 0.03 N/M 7 
 Zhu et al. N/M 0.16 N/M 0.16 0.09 N/M N/M N/M N/M N/M N/M N/M N/M N/M 8 
 Chen et al. N/M 0.40 N/M N/M 0.55 N/M N/M N/M N/M N/M N/M N/M N/M N/M 8 
Liu et al. N/M 0.33 N/M N/M N/M N/M 0.17 0.17 N/M N/M N/M N/M    Chill- 42% 7 
Chen et al. N/M 0.22 N/M 0.30 0.38 N/M 0.09 0.06 0.07 0.08 0.24 0.04 0.03 N/M 16 
 Mo et al. N/M 0.61 N/M N/M 0.39 0.04 0.04 0.04 0.02 0.02 0.32 N/M   N/M 14 
 Liu et al. N/M 0.32 N/M 0.04 N/M N/M N/M N/M N/M N/M N/M N/M 0.05 Heart palpitation-7%  10 
 Jin et al. 0.15 0.11 N/M 0.35 N/M N/M N/M N/M N/M N/M N/M N/M 0.02 Nasal Obstruction-6%,  9 
Wang et al. N/M 0.35 N/M 0.27 N/M N/M 0.10 0.04 N/M 0.09 0.40 0.17 N/M N/M 13 
Yuan et al. N/M 0.11 N/M N/M N/M N/M N/M N/M N/M N/M N/M N/M N/M N/M 4 








Liu et al. N/M N/M N/M N/M 0.07 N/M N/M 0.17 N/M N/M N/M N/M N/M  Nasal congestion-5%,  6 
Zhou et al. 0.06 0.34 N/M 0.42 0.26 N/M N/M N/M N/M 0.07 N/M N/M N/M N/M 10 
 Huang et al. N/M 0.44 N/M 0.28 N/M N/M N/M N/M N/M N/M N/M N/M 0.05 N/M 9 
 Chen et al. 0.05 0.11 0.04 N/M N/M 0.02 0.01 0.01 N/M N/M N/M N/M N/M N/M 10 
 Du et al. N/M 0.17 N/M 0.38 N/M 0.02 N/M 0.05 0.04 N/M 0.57 0.02 N/M N/M 14 
 Xu et al. 0.26 0.28 N/M 0.12 N/M N/M 0.06 0.02 N/M N/M N/M N/M N/M   Chills-7% 11 
Goyal et al. N/M 0.19 N/M N/M N/M N/M 0.19 0.19 N/M N/M N/M N/M N/M N/M 7 
 Barrasa et al. N/M 0.04 N/M N/M N/M N/M N/M N/M N/M N/M N/M N/M N/M Malaise-44% 5 
 Yan et al. 0.32 0.63 0.31 N/M N/M N/M 0.27 N/M N/M N/M N/M N/M N/M Nasal obstruction 
47.5%, Anosmia 68%, 
Ageusia 71% 
13 
 Gupta et al. 0.24 N/M N/M N/M N/M N/M N/M N/M N/M N/M N/M N/M N/M N/M 5 
Yang et al. 0.14 0.03 N/M 0.32 0.10 0.03 0.01 0.01 N/M N/M N/M N/M N/M  Chill-14%,   Snotty-
3% 
14 
 Han et al. N/M 0.21 N/M N/M 0.24 N/M N/M 0.12 0.04 N/M N/M 0.06 N/M  Poor apitite-34% 11 
 Kim et al. 0.29 0.25 0.07 0.21 N/M N/M N/M N/M 0.04 N/M N/M N/M N/M N/M 10 
 Wang et al. N/M 0.05 N/M 0.28 0.26 N/M 0.04 N/M N/M 0.04 0.28 0.04 N/M N/M 13 
 Shi et al. N/M N/M 0.26 0.19 0.22 N/M N/M 0.05 N/M 0.02 0.01 N/M N/M N/M 12 
Yang et al. N/M 0.12 0.06 N/M N/M 0.02 N/M 0.04 N/M N/M N/M N/M N/M  Malaise-35%,  
Arthralgia-2% 
10 
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Malignancy ARDS Others No. of 
Comorbi
dities 
 Wan et al. 0.09 0.10 0.05 N/M N/M 0.007 0.02 N/M N/M 0.03 N/M N/M 6 







 Xu et al. 0.02 0.08 N/M N/M 0.02 0.020 0.11 0.02 N/M N/M N/M N/M 6 
 Zhu et al. 0.13 0.22 N/M 0.06 0.03 0.060 0.06 0.03 N/M N/M N/M Mental disorder- 3%, 
Tumor-6% 
9 
 Chen et al. 0.14 0.24 N/M N/M N/M N/M N/M N/M N/M N/M N/M N/M 2 




Chen et al. 0.17 0.34 0.08 N/M 0.01 0.070 N/M N/M 0.01 0.03 N/M HBV infection-4%,   
Metabolic arthritis & 
Autoimmune disease 
& Gastro Intestinal 
disease- 1% 
11 
 Mo et al. 0.10 0.24 0.10 N/M 0.05 0.030 0.05 0.04 N/M 0.05 N/M Tuberculosis-2%, 
HIV-1% 
10 
 Liu et al. 0.10 0.10 0.07 N/M N/M 0.015 N/M N/M N/M 0.02 N/M N/M 5 
 Jin et al. 0.07 0.15 N/M 0.01 N/M 0.002 0.04 0.01 N/M 0.01 N/M Immunosuppression-
0.17%, 
8 
Wang et al. 0.10 0.31 0.15 N/M 0.05 0.030 0.03 N/M 0.03 0.07 N/M HIV infection-1% 9 
Yuan et al. 0.22 0.19 0.11 N/M N/M N/M N/M N/M N/M N/M 0.41 Tumor & Cerebral 
infraction & Chronic 
gastric- 4% 
9 




Liu et al. 0.07 0.17 N/M 0.11 N/M N/M 0.06 N/M 0.03 N/M N/M Persistent arterial 
fibrilliation-6%, 
6 
Zhou et al. 0.10 0.25 0.05 0.07 N/M 0.020 0.01  N/M 0.01 N/M HIV infection-0.4%, 8 
 Huang et al. 0.20 0.15 0.15 N/M N/M 0.020 0.02 N/M N/M 0.02 N/M N/M 6 





 Du et al. 0.22 0.38 0.08 0.12 N/M 0.020 0.06 N/M 0.04 0.07 N/M N/M 8 
 Xu et al. 0.06 0.19 0.03 N/M N/M 0.010 N/M N/M N/M 0.02 N/M Tuberculosis-2%, 6 
Goyal et al. 0.25 0.50 N/M 0.14 N/M 0.050 N/M N/M N/M N/M N/M Asthama-12.5%, 
Obesity-35% 
6 




 Yan et al. 0.09 0.14 0.05 N/M N/M 0.050 N/M N/M N/M 0.04 N/M Allergic rhinitis-34%, 
Sinus disease 3% 
7 






Yang et al. N/M N/M 0.19 N/M 0.19 N/M N/M N/M N/M  N/M Respiratory system 
disease - 0.67%, 
Digestive system 
disease- 5%, 
Endocrine disease- 6% 
5 
 Han et al. 0.10 0.27 N/M N/M 0.08 0.040 N/M N/M N/M N/M N/M N/M 4 
 Kim et al. 0.07 N/M N/M N/M  N/M 0.04  N/M 0.04 N/M Obesity-18%, 
Asthama-4% 
5 
 Wang et al. 0.16 0.41 0.16 N/M 0.06 0.060 0.01 N/M 0.04 0.04 N/M Autoimmune disease-
1.5% 
9 
 Shi et al. 0.12 0.15 0.10 N/M 0.07 0.110 0.09 0.04 N/M 0.05 N/M N/M 8 
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Pooled estimation of the symptoms and comorbidities 
Symptoms 







Overall  (I^2 = 90.67%, p = 0.00)
Gupta et al. (N=21) (New Delhi, India)
Chen et al. (N=99) (Wuhan, China)
Yang et al. (N=52) (Wuhan, China)
Barrasa et al. (N=48) (Vitoria, Spain)
Mo et al. (N=155) (Wuhan, China)
Wang et al. (N=339) (Wuhan, China)
Zhang et al. (N=140) (Wuhan, China)
Yan et al. (N=59) (USA)
Chen et al. (N=274) (Wuhan, China)
Goyal et al. (N=393) (New york, USA)
Chen et al. (N=21) (Wuhan, China)
Liu et al. (N=137) (Hubei, China)
Xu et al. (N=62) (Zhejiang, China)
Jin et al. (N=651) (Zhejiang, China)
Huang et al. (N=41) (Wuhan, China)
Study
Wang et al. (N=138) (Wuhan, China)
Yang et al. (N=149) (Wenzhou, China)
Wan et al. (N=135) (Chongqing, China)
Xu et al. (N=90) (Guangzhou, China)
Liu et al. (N=56) (Hainan, China)
Shi et al. (N=81) (Wuhan, China)
Du et al. (N=85) (Wuhan, China)
Guan et al. (N=1099) (30 provincees, China)
Han et al. (N=206) (Wuhan, China)
Zhu et al. (N=32) (Anhui, China)
Kim et al. (N=28) (South korea)
Liu et al. (N=12) (Shenzhen, China)
Yuan et al. (N=27) (Hubei, China)



































Meta-analysis of the prevalence of clinical symptom (Fever) in COVID-19 infected patients
S2. Fever
Pooled estimation of the symptoms and comorbidities
Symptoms







Overall  (I^2 = 93.40%, p = 0.00)
Chen et al. (N=99) (Wuhan, China)
Yan et al. (N=59) (USA)
Liu et al. (N=56) (Hainan, China)
Chen et al. (N=274) (Wuhan, China)
Study
Yang et al. (N=149) (Wenzhou, China)
Liu et al. (N=12) (Shenzhen, China)
Xu et al. (N=62) (Zhejiang, China)
Barrasa et al. (N=48) (Vitoria, Spain)
Jin et al. (N=651) (Zhejiang, China)
Goyal et al. (N=393) (New york, USA)
Mo et al. (N=155) (Wuhan, China)
Yang et al. (N=52) (Wuhan, China)
Huang et al. (N=41) (Wuhan, China)
Kim et al. (N=28) (South korea)
Shi et al. (N=81) (Wuhan, China)
Guan et al. (N=1099) (30 provincees, China)
Gupta et al. (N=21) (New Delhi, India)
Chen et al. (N=21) (Wuhan, China)
Xu et al. (N=90) (Guangzhou, China)
Zhu et al. (N=32) (Anhui, China)
Wang et al. (N=138) (Wuhan, China)
Zhou et al. (N=254) (Wuhan, China)
Han et al. (N=206) (Wuhan, China)
Liu et al. (N=137) (Hubei, China)
Zhang et al. (N=140) (Wuhan, China)
Wang et al. (N=339) (Wuhan, China)
Yuan et al. (N=27) (Hubei, China)
Wan et al. (N=135) (Chongqing, China)



































Meta-analysis of the prevalence of clinical symptom (Cough) in COVID-19 infected patients
S3. Cough / Dry Cough











Overall  (I^2 = 96.32%, p = 0.00)
Wang et al. (N=138) (Wuhan, China)
Wang et al. (N=339) (Wuhan, China)
Kim et al. (N=28) (South korea)
Han et al. (N=206) (Wuhan, China)
Guan et al. (N=1099) (30 provincees, China)
Study
Zhu et al. (N=32) (Anhui, China)
Xu et al. (N=62) (Zhejiang, China)
Wan et al. (N=135) (Chongqing, China)
Shi et al. (N=81) (Wuhan, China)
Chen et al. (N=274) (Wuhan, China)
Mo et al. (N=155) (Wuhan, China)
Huang et al. (N=41) (Wuhan, China)
Liu et al. (N=137) (Hubei, China)
Jin et al. (N=651) (Zhejiang, China)
Xu et al. (N=90) (Guangzhou, China)
Chen et al. (N=21) (Wuhan, China)
Zhang et al. (N=140) (Wuhan, China)
Yan et al. (N=59) (USA)
Zhou et al. (N=254) (Wuhan, China)
Liu et al. (N=56) (Hainan, China)


























Meta-analysis of the prevalence of clinical symptom (Fatigue) in COVID-19 infected patients
S4. Fatigue/Weakness









Overall  (I^2 = 97.37%, p = 0.00)
Goyal et al. (N=393) (New york, USA)
Study
Wang et al. (N=339) (Wuhan, China)
Chen et al. (N=21) (Wuhan, China)
Barrasa et al. (N=48) (Vitoria, Spain)
Huang et al. (N=41) (Wuhan, China)
Yan et al. (N=59) (USA)
Yang et al. (N=149) (Wenzhou, China)
Yang et al. (N=52) (Wuhan, China)
Yuan et al. (N=27) (Hubei, China)
Wang et al. (N=138) (Wuhan, China)
Zhou et al. (N=254) (Wuhan, China)
Chen et al. (N=274) (Wuhan, China)
Liu et al. (N=137) (Hubei, China)
Du et al. (N=85) (Wuhan, China)
Mo et al. (N=155) (Wuhan, China)
Zhang et al. (N=140) (Wuhan, China)
Wan et al. (N=135) (Chongqing, China)
























Meta-analysis of the prevalence of clinical symptom (Dyspnea) in COVID-19 infected patients
S5. Dyspnea/Shortness of breath








Overall  (I^2 = 89.98%, p = 0.00)
Shi et al. (N=81) (Wuhan, China)
Zhou et al. (N=254) (Wuhan, China)
Xu et al. (N=90) (Guangzhou, China)
Yang et al. (N=149) (Wenzhou, China)
Wan et al. (N=135) (Chongqing, China)
Xiaobo Yang (N=52) (Wuhan, China)
Gupta et al. (N=21) (New Delhi, India)
Yan et al. (N=59) (USA)
Jin et al. (N=651) (Zhejiang, China)
Du et al. (N=85) (Wuhan, China)
Chen et al. (N=274) (Wuhan, China)
Wang et al. (N=339) (Wuhan, China)
Guan et al. (N=1099) (30 provincees, China)
Chen et al. (N=99) (Wuhan, China)
Xu et al. (N=62) (Zhejiang, China)
Wang et al. (N=138) (Wuhan, China)
Study
Mo et al. (N=155) (Wuhan, China)
Chen et al. (N=21) (Wuhan, China)
Zhu et al. (N=32) (Anhui, China)
Kim et al. (N=28) (South korea)
Liu et al. (N=137) (Hubei, China)




























Meta-analysis of the prevalence of clinical symptom (Headache) in COVID-19 infected patients
S6. Headache




S8. Sore Throat 
Overall  (I^2 = 93.72%, p = 0.00)
Xu et al. (N=62) (Zhejiang, China)
Study
Guan et al. (N=1099) (30 provincees, China)
Wan et al. (N=135) (Chongqing, China)
Han et al. (N=206) (Wuhan, China)
Xu et al. (N=90) (Guangzhou, China)
Huang et al. (N=41) (Wuhan, China)
Goyal et al. (N=393) (New york, USA)
Zhu et al. (N=32) (Anhui, China)
Du et al. (N=85) (Wuhan, China)
Chen et al. (N=99) (Wuhan, China)
Liu et al. (N=137) (Hubei, China)
Liu et al. (N=12) (Shenzhen, China)
Yan et al. (N=59) (USA)
Mo et al. (N=155) (Wuhan, China)
Chen et al. (N=21) (Wuhan, China)
Kim et al. (N=28) (South korea)
Shi et al. (N=81) (Wuhan, China)
Chen et al. (N=274) (Wuhan, China)
Wang et al. (N=339) (Wuhan, China)
Wang et al. (N=138) (Wuhan, China)
Zhang et al. (N=140) (Wuhan, China)




























Meta-analysis of the prevalence of clinical symptom (Diarrhea) in COVID-19 infected patients
S7. Diarrhea






   S9. Myalgia/Muscle Ache 
Overall  (I^2 = 84.99%, p = 0.00)
Xu et al. (N=90) (Guangzhou, China)
Study
Kim et al. (N=28) (South korea)
Gupta et al. (N=21) (New Delhi, India)
Yan et al. (N=59) (USA)
Chen et al. (N=99) (Wuhan, China)
Zhou et al. (N=254) (Wuhan, China)
Guan et al. (N=1099) (30 provincees, China)
Yang et al. (N=149) (Wenzhou, China)














Meta-analysis of the prevalence of clinical symptom (Sore Throat) in COVID-19 infected patients
S8. Sore Throat







Overall  (I^2 = 95.00%, p = 0.00)
Yang et al. (N=52) (Wuhan, China)
Barrasa et al. (N=48) (Vitoria, Spain)
Du et al. (N=85) (Wuhan, China)
Liu et al. (N=12) (Shenzhen, China)
Yang et al. (N=149) (Wenzhou, China)
Yuan et al. (N=27) (Hubei, China)
Zhu et al. (N=32) (Anhui, China)
Jin et al. (N=651) (Zhejiang, China)
Goyal et al. (N=393) (New york, USA)
Huang et al. (N=41) (Wuhan, China)
Guan et al. (N=1099) (30 provincees, China)
Zhou et al. (N=254) (Wuhan, China)
Yan et al. (N=59) (USA)
Liu et al. (N=137) (Hubei, China)
Han et al. (N=206) (Wuhan, China)
Chen et al. (N=274) (Wuhan, China)
Chen et al. (N=21) (Wuhan, China)
Xu et al. (N=90) (Guangzhou, China)
Wang et al. (N=138) (Wuhan, China)
Chen et al. (N=99) (Wuhan, China)
Xu et al. (N=62) (Zhejiang, China)
Kim et al. (N=28) (South korea)
Mo et al. (N=155) (Wuhan, China)
Wan et al. (N=135) (Chongqing, China)
































Meta-analysis of the prevalence of clinical symptom (Myalgia) in COVID-19 infected patients
S9. Myalgia/Muscle Ache




   
 S11. Sputum Production/Expectoration 
Overall  (I^2 = 88.01%, p = 0.00)
Chen et al. (N=99) (Wuhan, China)
Yan et al. (N=59) (USA)
Shi et al. (N=81) (Wuhan, China)
Yang et al. (N=52) (Wuhan, China)












Meta-analysis of the prevalence of clinical symptom (Rhinorrhea) in COVID-19 infected patients
S10. Rhinorrhea




S12. Chest tightness 
Overall  (I^2 = 92.31%, p = 0.00)
Xu et al. (N=90) (Guangzhou, China)
Du et al. (N=85) (Wuhan, China)
Shi et al. (N=81) (Wuhan, China)
Wan et al. (N=135) (Chongqing, China)
Zhu et al. (N=32) (Anhui, China)
Kim et al. (N=28) (South korea)
Huang et al. (N=41) (Wuhan, China)
Wang et al. (N=138) (Wuhan, China)
Zhou et al. (N=254) (Wuhan, China)
Jin et al. (N=651) (Zhejiang, China)
Study
Guan et al. (N=1099) (30 provincees, China)
Chen et al. (N=274) (Wuhan, China)
Wang et al. (N=339) (Wuhan, China)
Liu et al. (N=137) (Hubei, China)




















Meta-analysis of the prevalence of clinical symptom (Sputum Production) in COVID-19 infected patients
S11. Sputum Production/Expectoration
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S13. Chest pain 
Overall  (I^2 = 88.44%, p = 0.00)
Chen et al. (N=274) (Wuhan, China)
Liu et al. (N=56) (Hainan, China)
Chen et al. (N=21) (Wuhan, China)
Yang et al. (N=149) (Wenzhou, China)
Han et al. (N=206) (Wuhan, China)
Zhou et al. (N=254) (Wuhan, China)
Mo et al. (N=155) (Wuhan, China)
Wang et al. (N=339) (Wuhan, China)
Shi et al. (N=81) (Wuhan, China)
Zhu et al. (N=32) (Anhui, China)


















Meta-analysis of the prevalence of clinical symptom (Chest Tightness) in COVID-19 infected patients
S12. Chest tightness




  S14. Nausea 
Overall  (I^2 = 0.00%, p = 0.95)
Mo et al. (N=155) (Wuhan, China)
Chen et al. (N=99) (Wuhan, China)
Du et al. (N=85) (Wuhan, China)
Yang et al. (N=149) (Wenzhou, China)












Meta-analysis of the prevalence of clinical symptom (Chest Pain) in COVID-19 infected patients
S13. Chest pain
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S15. Vomiting 
Overall  (I^2 = 91.78%, p = 0.00)
Liu et al. (N=12) (Shenzhen, China)
Study
Mo et al. (N=155) (Wuhan, China)
Wang et al. (N=339) (Wuhan, China)
Yan et al. (N=59) (USA)
Yang et al. (N=149) (Wenzhou, China)
Wang et al. (N=138) (Wuhan, China)
Xu et al. (N=90) (Guangzhou, China)
Guan et al. (N=1099) (30 provincees, China)
Chen et al. (N=99) (Wuhan, China)
Chen et al. (N=274) (Wuhan, China)
Zhang et al. (N=140) (Wuhan, China)


















Meta-analysis of the prevalence of clinical symptom (Nausea) in COVID-19 infected patients
S14. Nausea
AGE-RELATED RISK FACTORS AND SEVERITY OF SARS-COV-2 INFECTION
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S16. Abdominal Pain 
Overall  (I^2 = 88.33%, p = 0.00)
Guan et al. (N=1099) (30 provincees, China)
Xu et al. (N=90) (Guangzhou, China)
Shi et al. (N=81) (Wuhan, China)
Mo et al. (N=155) (Wuhan, China)
Yang et al. (N=149) (Wenzhou, China)
Yang et al. (N=52) (Wuhan, China)
Wang et al. (N=138) (Wuhan, China)
Du et al. (N=85) (Wuhan, China)
Liu et al. (N=12) (Shenzhen, China)
Chen et al. (N=274) (Wuhan, China)
Liu et al. (N=56) (Hainan, China)
Goyal et al. (N=393) (New york, USA)
Study
Han et al. (N=206) (Wuhan, China)




















Meta-analysis of the prevalence of clinical symptom (Vomiting) in COVID-19 infected patients
S15. Vomiting





Overall  (I^2 = 22.89%, p = 0.26)
Chen et al. (N=274) (Wuhan, China)
Han et al. (N=206) (Wuhan, China)
Zhang et al. (N=140) (Wuhan, China)
Du et al. (N=85) (Wuhan, China)
Mo et al. (N=155) (Wuhan, China)
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S16. Abdominal Pain
AGE-RELATED RISK FACTORS AND SEVERITY OF SARS-COV-2 INFECTION
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S18. Anorexia 
Overall  (I^2 = 64.21%, p = 0.02)
Zhou et al. (N=254) (Wuhan, China)
Chen et al. (N=274) (Wuhan, China)
Goyal et al. (N=393) (Wuhan, China)
Wang et al. (N=138) (Wuhan, China)
Mo et al. (N=155) (Wuhan, China)












Meta-analysis of the prevalence of clinical symptom (Dizziness) in COVID-19 infected patients
S17. Dizziness





Overall  (I^2 = 94.47%, p = 0.00)
Study
Du et al. (N=85) (Wuhan, China)
Chen et al. (N=274) (Wuhan, China)
Shi et al. (N=81) (Wuhan, China)
Wang et al. (N=138) (Wuhan, China)
Goyal et al. (N=393) (Wuhan, China)
Mo et al. (N=155) (Wuhan, China)
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S18. Anorexia
AGE-RELATED RISK FACTORS AND SEVERITY OF SARS-COV-2 INFECTION
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S20. Haemoptysis 
Overall  (I^2 = 88.03%, p = 0.00)
Study
Chen et al. (N=274) (Wuhan, China)
Wang et al. (N=138) (Wuhan, China)
Du et al. (N=85) (Wuhan, China)
Wan et al. (N=135) (Chongqing, China)
Wang et al. (N=339) (Wuhan, China)












Meta-analysis of the prevalence of clinical symptom (Pharyngalgia) in COVID-19 infected patients
S19. Pharyngalgia





  S21. Diabetes 
Overall  (I^2 = 63.48%, p = 0.01)
Huang et al. (N=41) (Wuhan, China)
Guan et al. (N=1099) (30 provincees, China)
Chen et al. (N=274) (Wuhan, China)
Liu et al. (N=137) (Hubei, China)
Jin et al. (N=651) (Zhejiang, China)
Xu et al. (N=62) (Zhejiang, China)
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S20. Haemoptysis
AGE-RELATED RISK FACTORS AND SEVERITY OF SARS-COV-2 INFECTION
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Overall  (I^2 = 83.09%, p = 0.00)
Yang et al. (N=52) (Wuhan, China)
Shi et al. (N=81) (Wuhan, China)
Xu et al. (N=62) (Zhejiang, China)
Jin et al. (N=651) (Zhejiang, China)
Xu et al. (N=90) (Guangzhou, China)
Zhang et al. (N=140) (Wuhan, China)
Yan et al. (N=59) (USA)
Wang et al. (N=138) (Wuhan, China)
Han et al. (N=206) (Wuhan, China)
Huang et al. (N=41) (Wuhan, China)
Goyal et al. (N=393) (New york, USA)
Gupta et al. (N=21) (New Delhi, India)
Zhu et al. (N=32) (Anhui, China)
Wang et al. (N=339) (Wuhan, China)
Chen et al. (N=274) (Wuhan, China)
Mo et al. (N=155) (Wuhan, China)
Barrasa et al. (N=48) (Vitoria, Spain)
Du et al. (N=85) (Wuhan, China)
Guan et al. (N=1099) (30 provincees, China)
Chen et al. (N=21) (Wuhan, China)
Zhou et al. (N=254) (Wuhan, China)
Liu et al. (N=56) (Hainan, China)
Kim et al. (N=28) (South korea)
Liu et al. (N=137) (Hubei, China)
Liu et al. (N=12) (Shenzhen, China)
Yuan et al. (N=27) (Hubei, China)


































Meta-analysis of the prevalence of clinical comorbidity (Diabetes) in COVID-19 infected patients
S21. Diabetes
Comorbidity




 S23. Cardiovascular Disease 
Overall  (I^2 = 93.24%, p = 0.00)
Gupta et al. (N=21) (New Delhi, India)
Chen et al. (N=274) (Wuhan, China)
Liu et al. (N=12) (Shenzhen, China)
Goyal et al. (N=393) (New york, USA)
Yan et al. (N=59) (USA)
Shi et al. (N=81) (Wuhan, China)
Xu et al. (N=62) (Zhejiang, China)
Wan et al. (N=135) (Chongqing, China)
Du et al. (N=85) (Wuhan, China)
Jin et al. (N=651) (Zhejiang, China)
Wang et al. (N=339) (Wuhan, China)
Barrasa et al. (N=48) (Vitoria, Spain)
Liu et al. (N=137) (Hubei, China)
Guan et al. (N=1099) (30 provincees, China)
Huang et al. (N=41) (Wuhan, China)
Wang et al. (N=138) (Wuhan, China)
Study
Yuan et al. (N=27) (Hubei, China)
Liu et al. (N=56) (Hainan, China)
Chen et al. (N=21) (Wuhan, China)
Xu et al. (N=90) (Guangzhou, China)
Han et al. (N=206) (Wuhan, China)
Zhou et al. (N=254) (Wuhan, China)
Zhang et al. (N=140) (Wuhan, China)
Zhu et al. (N=32) (Anhui, China)































Meta-analysis of the prevalence of clinical comorbidity (Hypertension) in COVID-19 infected patients
S22. Hypertension




















S24. Coronary heart disease 
Overall  (I^2 = 73.96%, p = 0.00)
Du et al. (N=85) (Guangzhou, China)
Shi et al. (N=81) (Wuhan, China)
Du et al. (N=85) (Wuhan, China)
Chen et al. (N=274) (Wuhan, China)
Mo et al. (N=155) (Wuhan, China)
Yang et al. (N=52) (Wuhan, China)
Yan et al. (N=59) (USA)
Huang et al. (N=41) (Wuhan, China)
Yang et al. (N=149) (Wenzhou, China)
Wan et al. (N=135) (Chongqing, China)
Wang et al. (N=339) (Wuhan, China)
Liu et al. (N=137) (Hubei, China)
Wang et al. (N=138) (Wuhan, China)
Zhou et al. (N=254) (Wuhan, China)
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S23. Cardiovascular Disease




 S25. Cerebrovascular disease 
Overall  (I^2 = 92.21%, p = 0.00)
Zhou et al. (N=254) (Wuhan, China)
Du et al. (N=85) (Wuhan, China)
Zhang et al. (N=140) (Wuhan, China)
Liu et al. (N=56) (Hainan, China)
Goyal et al. (N=393) (New york, USA)
Guan et al. (N=1099) (30 provincees, China)
Barrasa et al. (N=48) (Vitoria, Spain)
Jin et al. (N=651) (Zhejiang, China)
Liu et al. (N=12) (Shenzhen, China)

















Meta-analysis of the prevalence of clinical comorbidity (Coronary Heart Disease ) in COVID-19 infected patients
S24. Coronary heart disease















S26. COPD/Lung disease 
Overall  (I^2 = 90.77%, p = 0.00)
Shi et al. (N=81) (Wuhan, China)
Yang et al. (N=149) (Wenzhou, China)
Wang et al. (N=138) (Wuhan, China)
Chen et al. (N=274) (Wuhan, China)
Han et al. (N=206) (Wuhan, China)
Guan et al. (N=1099) (30 provincees, China)
Mo et al. (N=155) (Wuhan, China)
Wang et al. (N=339) (Wuhan, China)
Zhu et al. (N=32) (Anhui, China)
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S25. Cerebrovascular disease




S27. Chronic liver disease 
Overall  (I^2 = 86.67%, p = 0.00)
Wang et al. (N=138) (Wuhan, China)
Huang et al. (N=41) (Wuhan, China)
Xu et al. (N=90) (Guangzhou, China)
Han et al. (N=206) (Wuhan, China)
Zhu et al. (N=32) (Anhui, China)
Barrasa et al. (N=48) (Vitoria, Spain)
Du et al. (N=85) (Wuhan, China)
Mo et al. (N=155) (Wuhan, China)
Goyal et al. (N=393) (New york, USA)
Zhou et al. (N=254) (Wuhan, China)
Shi et al. (N=81) (Wuhan, China)
Jin et al. (N=651) (Zhejiang, China)
Xu et al. (N=62) (Zhejiang, China)
Zhang et al. (N=140) (Wuhan, China)
Liu et al. (N=137) (Hubei, China)
Chen et al. (N=274) (Wuhan, China)
Guan et al. (N=1099) (30 provincees, China)
Yan et al. (N=59) (USA)
Liu et al. (N=12) (Shenzhen, China)
Wang et al. (N=339) (Wuhan, China)



























Meta-analysis of the prevalence of clinical comorbidity (COPD) in COVID-19 infected patients
S26. COPD/Lung disease





















S28. Chronic Renal disease 
Overall  (I^2 = 78.23%, p = 0.00)
Mo et al. (N=155) (Wuhan, China)
Shi et al. (N=81) (Wuhan, China)
Yang et al. (N=52) (Wuhan, China)
Wan et al. (N=135) (Chongqing, China)
Huang et al. (N=41) (Wuhan, China)
Du et al. (N=85) (Wuhan, China)
Xu et al. (N=62) (Zhejiang, China)
Liu et al. (N=56) (Hainan, China)
Zhou et al. (N=254) (Wuhan, China)
Zhang et al. (N=140) (Wuhan, China)
Wang et al. (N=138) (Wuhan, China)
Kim et al. (N=28) (South korea)
Kim et al. (N=28) (Wuhan, China)
Study
Zhu et al. (N=32) (Anhui, China)




















Meta-analysis of the prevalence of clinical comorbidity (Chronic Liver Disease) in COVID-19 infected patients
S27. Chronic liver disease





S29. Chronic Kidney disease 
 
Overall  (I^2 = 54.63%, p = 0.02)
Zhang et al. (N=140) (Wuhan, China)
Zhu et al. (N=32) (Anhui, China)
Chen et al. (N=99) (Wuhan, China)
Xu et al. (N=62) (Zhejiang, China)
Mo et al. (N=155) (Wuhan, China)
Liu et al. (N=12) (Shenzhen, China)
Guan et al. (N=1099) (30 provincees, China)
Shi et al. (N=81) (Wuhan, China)















Meta-analysis of the prevalence of clinical comorbidity (Chronic Renal Disease) in COVID-19 infected patients
Overall  (I^2 = 86.69%, p = 0.00)
Yingzhen Du et al. (N=85) (Wuhan, China)
Study
DaweiWang et al. (N=138) (Wuhan, China)
Lang Wang et al. (N=339) (Wuhan, China)
Tao Chen et al. (N=274) (Wuhan, China)
Xiaobo Yang (N=52) (Wuhan, China)
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S28. Chronic Renal disease





S29. Chronic Kidney disease 
 
Overall  (I^2 = 54.63%, p = 0.02)
Zhang et al. (N=140) (Wuhan, China)
Zhu et al. (N=32) (Anhui, China)
Chen et al. (N=99) (Wuhan, China)
Xu et al. (N=62) (Zhejiang, China)
Mo et al. (N=155) (Wuhan, China)
Liu et al. (N=12) (Shenzhen, China)
Guan et al. (N=1099) (30 provincees, China)
Shi et al. (N=81) (Wuhan, China)















Meta-analysis of the prevalence of clinical comorbidity (Chronic Renal Disease) in COVID-19 infected patients
Overall  (I^2 = 86.69%, p = 0.00)
Yingzhen Du et al. (N=85) (Wuhan, China)
Study
DaweiWang et al. (N=138) (Wuhan, China)
Lang Wang et al. (N=339) (Wuhan, China)
Tao Chen et al. (N=274) (Wuhan, China)
Xiaobo Yang (N=52) (Wuhan, China)












Meta-analysis of the prevalence of clinical comorbidity (Chronic Kidney Disease) in COVID-19 infected patients
S29. Chronic Kidney disease


























S30.  Malignancy 
 
  
Overall  (I^2 = 68.06%, p = 0.00)
Mo et al. (N=155) (Wuhan, China)
Wang et al. (N=339) (Wuhan, China)
Huang et al. (N=41) (Wuhan, China)
Yan et al. (N=59) (USA)
Zhou et al. (N=254) (Wuhan, China)
Du et al. (N=85) (Wuhan, China)
Guan et al. (N=1099) (30 provincees, China)
Wang et al. (N=138) (Wuhan, China)
Kim et al. (N=28) (South korea)
Chen et al. (N=274) (Wuhan, China)
Jin et al. (N=651) (Zhejiang, China)
Liu et al. (N=137) (Hubei, China)
Xu et al. (N=90) (Guangzhou, China)
Shi et al. (N=81) (Wuhan, China)
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S30. alignancy










Overall  (I^2 = 98.07%, p = 0.00)
Chen et al. (N=99) (Wuhan, China)
Study
Barrasa et al. (N=48) (Vitoria, Spain)
Yuan et al. (N=27) (Hubei, China)
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S31. ARDS
